Good morning. My name is Crystal, and I will be your conference operator today. At this time, I would like to welcome everyone to the WhiteHorse Finance Second Quarter 2018 Earnings Conference Call. Our hosts for today's call are Stuart Aronson, Chief Executive Officer; and Ed Giordano, Interim Chief Financial Officer. Today's call is being recorded and will be available for replay beginning at 1:00 p.m. Eastern Standard Time. The replay dial-in number is 404-537-3406 and the PIN number is 2791007. At this time, all participants have been placed on a listen-only mode and the floor will be opened for your questions following the presentation. [Operator Instructions] It is now my pleasure to turn the floor over to Sean Silva of Prosek Partners.

Thank you, Crystal, and thank you, everyone, for joining us today to discuss WhiteHorse Finance's Second Quarter 2018 Earnings Results. Before we begin, I would like to remind everyone that certain statements which are not based on historical facts made during this call, including any statements relating to financial guidance, may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because these forward-looking statements involve known and unknown risks and uncertainties, these are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. WhiteHorse Finance assumes no obligation or responsibility to update any forward-looking statements. With that, allow me to introduce WhiteHorse Finance's CEO, Stuart Aronson. Stuart, you may begin.

Thanks, Sean. Good morning, and thank you for joining us today. As you're aware, we issued our press release this morning prior to market open, and I hope you've had a chance to review our results, which are also available on our website. I'm going to take you through our second quarter operating performance, and then Ed will review our financial results, after which we will take your questions. During the second quarter, we continued our positive momentum and delivered another strong set of results under the backdrop of a very competitive credit environment. We’ve recorded net asset value per share of $14.87 a $0.57 increase from the first quarter of 2018 and an increase of $1.04 from the second quarter of 2017. Additionally our weighted average effective yield held constant at 12.0%. Core net interest income was $0.331 per share, this excludes a $2.2 million accrual for capital gains incentive fee resulting from our markup during the quarter on Aretec. Ed will provide further detail on core versus GAAP net interest income shortly, prior to which I'll detail our top achievements during the quarter. First, our value and our position in Aretec grew to $37.4 million, which was later confirmed with Aretec's announced sale to Genstar. In marking that asset we took an appropriate discount for the possibility that the transaction will not close. However, if the transaction closes as contemplated, there will be further value accretion as that discount is turned into cash. In general as I've shared before, for every $2 million of cash we receive and invested at 10% yield at our historical target leverage, we typically increased net interest income by approximately $0.01 per share on an annual basis. Second, we recently held our Annual Shareholders Meeting where shareholders approved the proposal for increasing our…

Thanks Stuart. I’ll first address our Q2 results and conclude by discussing the July refinancing of our Senior notes. We recorded net investment income of $4.6 million or $0.224 per share. This accounts for GAAP reporting requirements that the recognition of capital gains based incentive fee be accrued if realized gains and unrealized appreciation of investments exceed realized losses and unrealized depreciation of investments. As such, during the quarter, we recognized an accrued expense of $2.2 million stemming from an unrealized gain driven by the continued markups of our position in Aretec. Core NII which excludes the accrual of capital gains incentive fee was $6.8 million for the quarter or $0.331 per share. This compares to $8.6 million or $0.418 per share in the prior quarter. Our investment income continues to consist primarily of recurring cash interest. We reported a net increase in net assets resulting from operations of approximately $19.1 million or $0.93 per share for the second quarter which includes $12.2 million markup of Aretec. As of June 30, 2018 net asset value was $305.3 million or $14.87 per share up from $293.5 million or $14.3 per share as reported for Q1. As it pertains to our portfolio and investment activity, the risk ratings of our portfolio saw modest improvements with three of our portfolio companies being upgraded to a 1 rating and another being upgraded from 3 to 2 rating. Turning to our balance sheet, we had cash resources of approximately $18.6 million as of June 30, including $4.1 million of restricted cash and approximately $12.2 million of undrawn capacity under our revolving credit facility. We continue to closely monitor our asset coverage ratio and feel comfortable with our leverage as of June 30, 2018. The company’s asset coverage ratio for borrowed amount as defined by the…

[Operator Instructions] Our first question comes from the line of Mickey Schleien with Ladenburg.

Yes. Good morning Stuart and Ed. I have a couple of more followup questions on Aretec. I understand obviously that it’s a private transactions Stuart, but it is a large position in the portfolio and you mentioned that it’s still carried as a discount to the exit price. Could you give us a sense at least whether the discount is single digit discount or are we talking a double-digit discount?

Good morning Mickey. I've got to be careful on that because the transaction while announced is still confidential vis-à-vis the actual pricing. I guess the best way to answer would be to say that at the end of the quarter the transaction had not been announced yet, and so if anything the level of certainty of the transaction has increased with our public announcements both of the transaction at of the financing for the transaction. But as of the end of the quarter we still felt there was a significant uncertainty and the discount to the final valuation is, well into the double digits.

Okay, that’s helpful Stuart. And I think from the press releases it said, that’s going to close next month which will provide you with a pretty meaningful amount of liquidity. I think in your prepared remarks you mentioned the pipeline, but do you think it’s large enough to absorb this level of liquidity or is it more likely that leverage will decline at least for a while?

So, Mickey, when we are working on building a pipeline for the BDC we are very cautious about getting involved in committing to things before we have the capital in. They said, the increased leverage is now approved and so we have flexibility on capital funding through increased leverage. So we are just now starting to work on ramping up the pipeline to be able to deploy that money. But as I shared in the remarks, both the increased leverage which provides the $61 million to $137 million of additional investing capacity and then the conversion of the RCS equity into cash will create a very significant amount of investing capacity and if we maintain our investment positions of no more than $20 million per transaction then it is best estimated that it will take us between 9 to 12 months to get to full deployment on all that asset. It will not occur in a quarter or two.

Okay that's helpful and just I don't want to beat a dead horse, but a couple more questions, more sort of housekeeping on Aretec. Will there be any dividend or fee income associated with that transaction and do you expect to distribute the realized gains to shareholders or retain the capital?

The expectation is that the gain on Aretec will be used to enhance the investing activities of the BDC and to make our ability to earn our dividend even more reliable than it is now. So we do not anticipate distributing those proceeds.

And, will there be any sort of fee or dividend income associated with it?

At the moment that has not been decided.

Okay, and just a couple more I may, the SLF I understand operates as an LLC, that terminates next year, although I understand there is a one-year extension possible. Do you expect the extension to be exercised and if you don’t do you expect to roll that into another SLF investment out there or just on to the balance sheet itself?

I don't have any data to share with you on that Mickey, I’m sorry.

Okay and just on - maybe for Ed, on the refinancing of the notes, can you quantify how much the write-up for the deferred financing costs will be and will that be reported as an operating expense or realized loss?

I don’t think I have that near at my fingertips Mickey, but…

I’ll followup with you later then.

It would be from the existing notes it be written off through the expenses.

Okay.

In this quarter.

Fine. I’ll followup with you when we figure it later today. Okay, thank you. That’s it for me.

Great, thank you Mickey.

Our next question comes from the line of Chris Kotowski with Oppenheimer.

My questions, but let me just ask, on redeploying the gain, let's just for arguments sake say it’s $20 million, the gain from Aretec, if you don't distribute that but retain it, is that like you have to pay a 4% annual excise tax on it so it’s like 4% debt financing almost, is that the way it would work on a go forward basis?

That’s right.

I’m sorry?

This is Ed speaking. Yes, that's right on the gain component.

Okay and it’s 4% a year forever, but 4% money is pretty good right?

Well, it’s a one-time 4%.

It's a one-time 4%, okay, yes. All right, well, that’s really good.

Mickey to circle back it’s $300,000 of deferred finance on the Baby Bonds that will be written off in Q3.

Okay and then, I guess the other question I have is – no actually I think that’s all my questions, thanks. Take care.

No problem. Thank you very much, have a good day.

Our next question comes from the line of Rick Shane with JPMorgan. Q –Unidentified Analyst: Melissa on for Rick today. I wanted to check in with you about the fee structure under the new increased leverage framework. Are you reducing fees on assets above a certain amount of leverage or will it remain flat? Thanks.

We have certainly noted the announcements that have been made by a number of other BDCs in regard to lower fees on assets that are invested at leverage at over one times and that will be an active discussion point among the management of the company, but no decisions on that have been reached at this time.

Okay and a similar question regarding dividend level and the potential to boost NII through this increase leverage. Any discussion at this point of potential dividend increase?

So, discussion of the dividend increase would need to occur after the money is invested and we have clarity and the market has clarity on what the net interest income being generated on a quarterly basis is. First and foremost, we see the increase in leverage providing us with an opportunity to rebalance the BDC between first lien and second lien and to create a safer portfolio of assets. We think we've been putting good second lien assets on the BDC. We've suffered only $1 million of nonaccrual on any of those second lien assets, but there is no argument that first lien assets are safer than second lien assets and so the first focus is in making the existing earnings of the BDC and the existing dividend more safe and more secure. If after we get the Aretec proceeds and invest the increased leverage in the BDC, there is sufficient ongoing income to justify a dividend increase. The management of the company and the board would consider that at that time. But again, I do indicate that it is likely to take 9 to 12 months to invest that capital. So while there is certainly the possibility of an increase in the future it would not be anything that would be determined in the near-term.

Okay thank you. One followup question on Aretec, I’m sorry if I missed it. Did you guys provide any guidance or context around potential timing of course understood it's not certainty of course at this point, but if that transaction were to close would that be a 3Q or a 4Q event?

The public stated intention of the buyer is that it would be a Q3 event, but as we all know things happen and so we don't know whether it would be most likely to occur in Q3 or Q4. Our assumption based on publicly available data is late Q3 or early Q4.

Got it, thank you.

Our next question comes from the line of Mickey Schleien with Ladenburg.

Mickey?

Hold one moment. Your line is open.

Ed, can you hear me?

Yes, we can hear you.

Just a followup…

Oh, we lost you again Mickey I think.

His line is still connected. Mickey?

I’m here.

We couldn’t hear your question Mickey.

Can you hear me now?

We can now, yes.

Okay I'll try once more. Just want to confirm on the excise tax question, I want to confirm what I think I heard that you will accrue for example on a $20 million gain an $800,000 excise tax at the time that the transaction closes, is that correct? Or but you won't pay it until you finish your tax return is that right?

That's right. I mean we will accrue it at the time the transaction happens and we determined not to make that distribution of the proceeds. So yes, it would be paid subsequently when the tax return is filed.

Okay and on the write off for the deferred financing, you said it was $300,000. Again, is that going to be an operating expense or a realized loss?

Operating expense will come through the interest expense.

Okay, perfect. That's it for me, thank you.

Yep, no problem. Thank you Mickey.

Our next question comes from the line of Troy Ward with Ares Management.

Good morning, Troy.

Hold for your question. Troy your line is open.

Great, thank you. Sir, can you hear me?

Yes, we can hear you.

All right, great. Can you give us an update on Grupo HIMA, I know it's a singular…

Did we lose the line?

Yes, one moment.

Okay.

[Operator Instructions]

And did we lose Troy or is Troy still on?

There is no response from his line at the moment.

Alright, well I heard at least the start of the question, so I’ll seek to answer it. Grupo HIMA continues to be in a in a long and complex restructuring the mission-critical nature of the services provided by the hospitals of Grupo HIMA are supportive of the fact that there is long-term value in that asset. We do believe that the overall capital structure through the second lien was overleveraged and therefore the second lien is both on nonaccrual and has been written down to $0.10. But the first lien leverage is at a very reasonable level, especially with the second lien on a non-cash pay basis and the company is making all scheduled payments as appropriate. I don't have an estimated timing for the resolution of the restructuring of that debt, but I do feel comfortable saying that the leverage level on the senior debt is not excessive and that through restructuring it is my hope that we will have enhanced value on the senior debt in the future. But given the current uncertainty and the slow pace of the restructuring discussions, we are holding that at what we believe is an appropriately conservative value in the mid-70s. Are there any other questions operator?

Not at this time.

Okay. I appreciate everybody's attention and if anyone wants to have a conversation separately, management always remains open to providing whatever data we can to our investors.